v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]    
Revenue $ 65,837 $ 46,850
Cost of revenue 32,136 39,125
Gross profit 33,701 7,725
Operating expenses:    
Selling, general and administrative 29,092 39,564
Research and development 3,889 4,888
Goodwill impairment 0 12,435
Restructuring 2,878 0
Total operating expenses 35,859 56,887
Loss from operations (2,158) (49,162)
Other income (expense):    
Interest expense (5,749) (6,778)
Interest income 1,873 3,225
Other (expense) income (494) 24
Loss before income taxes (6,528) (52,691)
Income tax (benefit) expense (151) 162
Net loss (6,377) (52,853)
Net loss attributable to non-controlling interests (2,644) (22,908)
Net loss attributable to Maravai LifeSciences Holdings, Inc. $ (3,733) $ (29,945)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic (in usd per share) $ (0.02) $ (0.21)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., diluted (in usd per share) $ (0.02) $ (0.21)
Weighted average number of Class A common shares outstanding, basic (in shares) 146,426 143,425
Weighted average number of Class A common shares outstanding, diluted (in shares) 146,426 143,425

Source